Stephen P. Hack
- Oncology top 1%
- Colorectal Cancer Treatments and Studies 12
- Pancreatic and Hepatic Oncology Research 9
- Peptidase Inhibition and Analysis 5
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis 9
- Molecular Biology top 5%
- Melanoma and MAPK Pathways 6
-
- Neuroscience and Neuropharmacology Research 6
- Gastroenterology top 5%
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 7
-
- Gastric Cancer Management and Outcomes 5
- Co-authors
- MacDonald J. ChristieL. ThomasMichele MaioMario MandalàGabriella LiszkayCaroline DutriauxLuis de la Cruz‐MerinoIlsung Chang
- Cited by
- OncologyHepatologyMolecular Biology
- Journals
- Journal of Clinical Oncology (11 papers)Annals of Oncology (4 papers)Journal of Neuroscience (2 papers)
- Partner nations
- United StatesUnited KingdomSouth Korea
In The Last Decade
Stephen P. Hack
40 papers receiving 3.1k citations
Hit Papers
Peers
Comparison fields: 5 of 103
- Oncology 1.7k
- Hepatology 369
- Molecular Biology 1.7k
- Cellular and Molecular Neuroscience 416
- Gastroenterology 103
Countries citing papers authored by Stephen P. Hack
This map shows the geographic impact of Stephen P. Hack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen P. Hack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen P. Hack more than expected).
Fields of papers citing papers by Stephen P. Hack
This network shows the impact of papers produced by Stephen P. Hack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen P. Hack. The network helps show where Stephen P. Hack may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Stephen P. Hack, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, studybreakdown → | 2025 | 26 |
| 3 | 2025 | 0 | |
| 4 | 2024 | 35 | |
| 5 | 2023 | 4 | |
| 6 | 2020 | 4 | |
| 7 | 2020 | 184 | |
| 8 | 2020 | 151 | |
| 9 | 2016 | 209 | |
| 10 | 2015 | 22 | |
| 11 | 2015 | 6 | |
| 12 | Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanomabreakdown → | 2014 | 1491 |
| 13 | 2013 | 26 | |
| 14 | 2013 | 30 | |
| 15 | 2005 | 61 | |
| 16 | 2005 | 66 | |
| 17 | 2004 | 52 | |
| 18 | 2004 | 58 | |
| 19 | 2003 | 73 | |
| 20 | 2003 | 39 |
About Stephen P. Hack
Stephen P. Hack is a scholar working on Hepatology, Oncology and Gastroenterology, having authored 42 papers that have together received 3.1k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Pancreatic and Hepatic Oncology Research (9 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Neuroscience and Neuropharmacology Research (6 papers), Melanoma and MAPK Pathways (6 papers), Peptidase Inhibition and Analysis (5 papers) and Gastric Cancer Management and Outcomes (5 papers). The work is most often cited by research in Oncology (1.7k citations), Hepatology (369 citations) and Molecular Biology (1.7k citations). Stephen P. Hack has collaborated with scholars based in United States, United Kingdom and South Korea. Frequent co-authors include MacDonald J. Christie, L. Thomas, Michele Maio, Mario Mandalà, Gabriella Liszkay, Caroline Dutriaux, Luis de la Cruz‐Merino, Ilsung Chang, Victoria Atkinson and Grant A. McArthur. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Neuroscience, Journal of Neurophysiology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.